These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 18625339)

  • 1. PK/PD: new insights for antibacterial and antiviral applications.
    Schmidt S; Barbour A; Sahre M; Rand KH; Derendorf H
    Curr Opin Pharmacol; 2008 Oct; 8(5):549-56. PubMed ID: 18625339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.
    Danhof M; de Lange EC; Della Pasqua OE; Ploeger BA; Voskuyl RA
    Trends Pharmacol Sci; 2008 Apr; 29(4):186-91. PubMed ID: 18353445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microdialysis for pharmacokinetic-pharmacodynamic studies.
    Yu W; Cheng Q; Feng J; Li F
    Pharmazie; 2007 Dec; 62(12):883-91. PubMed ID: 18214337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The importance of appropriate antimicrobial dosing: pharmacokinetic and pharmacodynamic considerations.
    Preston SL
    Ann Pharmacother; 2004 Sep; 38(9 Suppl):S14-8. PubMed ID: 15226489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tools to define the relevance of PK/PD parameters to the efficacy, toxicity and emergence of resistance of antimicrobials.
    Hickey E
    Curr Opin Drug Discov Devel; 2007 Jan; 10(1):49-52. PubMed ID: 17265741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combating resistance: application of the emerging science of pharmacokinetics and pharmacodynamics.
    Jacobs MR
    Int J Antimicrob Agents; 2007 Dec; 30 Suppl 2():S122-6. PubMed ID: 17936592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments.
    Nielsen EI; Viberg A; Löwdin E; Cars O; Karlsson MO; Sandström M
    Antimicrob Agents Chemother; 2007 Jan; 51(1):128-36. PubMed ID: 17060524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
    Avramis VI; Martin-Aragon S; Avramis EV; Asselin BL
    Anticancer Res; 2007; 27(4C):2561-72. PubMed ID: 17695416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PK/PD modelling and simulations: utility in drug development.
    Rajman I
    Drug Discov Today; 2008 Apr; 13(7-8):341-6. PubMed ID: 18405847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PK-PD modeling of protein drugs: implications in assay development.
    Roskos LK; Schneider A; Vainshtein I; Schwickart M; Lee R; Lu H; Faggioni R; Liang M
    Bioanalysis; 2011 Mar; 3(6):659-75. PubMed ID: 21417734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic-pharmacodynamic and response sensitization modeling of the intraocular pressure-lowering effect of the EP4 Agonist 5-{3-[(2S)-2-{(3R)-3-hydroxy-4-[3-(trifluoromethyl)phenyl]butyl}-5-oxopyrrolidin-1-yl]propyl}thiophene-2-carboxylate (PF-04475270).
    Luu KT; Zhang EY; Prasanna G; Xiang C; Anderson S; Fortner J; Vicini P
    J Pharmacol Exp Ther; 2009 Nov; 331(2):627-35. PubMed ID: 19690190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing pharmacokinetic variability directly induced by drug intake behaviour through development of a feeding behaviour-pharmacokinetic model.
    Li J; Petit-Jetté CE; Gohore Bi D; Fenneteau F; Del Castillo JR; Nekka F
    J Theor Biol; 2008 Apr; 251(3):468-79. PubMed ID: 18234231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of pharmacodynamic research in the assessment and development of new antibacterial drugs.
    Lister PD
    Biochem Pharmacol; 2006 Mar; 71(7):1057-65. PubMed ID: 16316633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibiotic dosing in children in Europe: can we grade the evidence from pharmacokinetic/pharmacodynamic studies - and when is enough data enough?
    Barker CI; Standing JF; Turner MA; McElnay JC; Sharland M
    Curr Opin Infect Dis; 2012 Jun; 25(3):235-42. PubMed ID: 22517604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling.
    Ince I; de Wildt SN; Tibboel D; Danhof M; Knibbe CA
    Drug Discov Today; 2009 Mar; 14(5-6):316-20. PubMed ID: 19059496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of PK-PD drug-drug interaction between acenocoumarol and amoxicillin plus clavulanic acid.
    Delavenne X; Laporte S; Demasles S; Mallouk N; Basset T; Tod M; Girard P; Mismetti P
    Fundam Clin Pharmacol; 2009 Feb; 23(1):127-35. PubMed ID: 19267776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics.
    Agoram BM; Martin SW; van der Graaf PH
    Drug Discov Today; 2007 Dec; 12(23-24):1018-24. PubMed ID: 18061880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic-pharmacodynamic target attainment analysis of doripenem in infected patients.
    Ikawa K; Morikawa N; Uehara S; Monden K; Yamada Y; Honda N; Kumon H
    Int J Antimicrob Agents; 2009 Mar; 33(3):276-9. PubMed ID: 19095418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of micafungin regimens by pharmacokinetic-pharmacodynamic analysis: a dosing strategy for Aspergillus infections.
    Ikawa K; Nomura K; Morikawa N; Ikeda K; Taniwaki M
    J Antimicrob Chemother; 2009 Oct; 64(4):840-4. PubMed ID: 19700475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multi-type branching model with varying environment for bacterial dynamics with postantibiotic effect.
    Geli P; Andersson M; Svensson A; Andersson DI
    J Theor Biol; 2009 Jan; 256(1):58-64. PubMed ID: 18952106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.